Clinical Trials Browser

Active not recruiting × High Grade Fallopian Tube Serous Adenocarcinoma × pembrolizumab × Clear all

NCT05114421 2025-08-07

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Phase 2 Active not recruiting

High Grade Fallopian Tube Serous Adenocarcinoma